An in vitro study on the development of immunotherapy using peptides derived from FJX1 as a treatment for head and neck cancer including NPC has shown the ability of these peptides to elicit patients' T cell cytotoxic response towards tumour cells expressing FJX1 [56, 57]. Here, FJX1 is linked to head and neck cancer.